SBRT has non-inferior acute and late-term toxicity vs IMRT in two randomized clinical trials

In October 2018, the American Society of Radiation Oncologists (ASTRO) strongly endorsed moderately hypofractionated IMRT (20 or 28 treatments) for primary radiation treatment (see this link). … READ MORE …

Nutrition, ADT, and metastatic prostate cancer

Most men who are taking androgen deprivation therapy (ADT) for metastatic prostate cancer feel the need to “do something” about their diet in order to (a) further help to control the risk for progression of their cancer and (b) help to cope with the side effects of ADT. … READ MORE …

Liver disease as an adverse event for men on ADT

A newly published article in the Journal of Urology has indicated risk of an association between treatment with androgen deprivation therapy (ADT) and risk for a spectrum of liver disorders. … READ MORE …

Common long-term side effects of ADT in treatment of prostate cancer

A new analysis of data from men treated for their prostate cancer between 1992 and 2009 has provided additional information with respect to risks for long-term side effects of androgen deprivation therapy (ADT). … READ MORE …

Risk for DVT and PE as a complication of treatment with ADT

A newly published paper in Prostate Cancer and Prostatic Diseases has confirmed that there is an association between specific forms of androgen deprivation therapy (ADT) and certain types of adverse thromboembolic events. … READ MORE …

PROs and HRQoL among patients participating in the LATITUDE trial

A newly published paper in The Lancet Oncology has provided early data from the LATITUDE trial on patient-reported outcomes (PROs) and health-related quality of life (HRQoL) for men with newly diagnosed, high-risk, metastatic, castration-naive prostate cancer. … READ MORE …

Are low serum levels of vitamin D a risk factor for aggressive forms of prostate cancer?

It has long between understood that there is an association between a man’s serum levels of vitamin D and his risk for prostate cancer in general and clinically significant prostate cancer in particular. … READ MORE …

Declining trend in the utilization of adjuvant radiation after surgery

A recent report in European Urology found that, in spite of three randomized clinical trials (RCTs) that proved the efficacy of immediate or adjuvant radiation following surgery with adverse pathology results compared to a wait-and-see approach, a lower percentage of such patients are actually getting adjuvant treatment. Why should this be? … READ MORE …

Is treatment with degarelix really “better” than treatment with an LHRH agonist? Part II

Yesterday we commented (by request) on a paper by Klotz et al. suggesting that initial treatment with the LHRH antagonist degarelix might have benefits compared to initial treatment with an LHRH agonist such as leuprolide or goserelin acetate. … READ MORE …

Heart-related mortality in men on ADT: a current perspective

A newly published study in BJU International suggests (unsurprisingly) that androgen deprivation therapy (ADT) is associated with an increased risk of death among men with such cardiovascular conditions as congestive heart failure or prior heart attacks. … READ MORE …

New ADT patients not well informed about possible side effects

The “New” Prostate Cancer InfoLink is utterly unsurprised to learn about a forthcoming paper demonstrating that many men starting treatment with androgen deprivation therapy (ADT) — and their partners — are significantly under-informed about the risk for side effects and adverse effects associated with such therapy. … READ MORE …

FDA updates risks of adverse effects from treatment with finasteride

The U.S. Food & Drug Adminstration (FDA), yesterday, issued a statement about modifications to the labeling (the product prescribing information) for the two branded formulations of finasteride: Propecia® (finasteride 1 mg) and Proscar® (finasteride 5 mg). These modifications to the product labeling may be relevant to some men with or at risk for prostate cancer. … READ MORE …

Prostate cancer news update: Tuesday, 9 September

This morning’s news update deals with two newly published studies:

  • The relative effectiveness of two different types of artificial sphincter for the chronically incontinent post-treatment
  • The impact of ADT on metabolic and cardiovascular processes and the risk for significant adverse reactions as a consequence of hypogonadism … READ MORE …